Extract

To compare the disease free survival time and safety of sunitinib with placebo in adjuvant treatment patients at high risk of recurrent kidney cancer after surgery.

Inclusion criteria

• Kidney Neoplasms

Country

• Australia
• China
• Colombia
• Czech Republic
• Denmark
• France
• Germany
• Greece
• Ireland
• Israel
• Italy
• Korea, Republic of
• Malaysia
• Mexico
• Poland
• Slovakia
• Spain
• Sweden
• Switzerland
• Taiwan, Province of China
• United Kingdom
• United States

Links

• ictrp
• nct